Page - (000346) - in Biomedical Chemistry: Current Trends and Developments

Coates, J. B., Hoff, E. C., & Hoff, P. M. (Eds.). (1963). PREVENTIVE MEDICINE IN WORLD WAR II: Volume VI, communicable diseases, malaria. Washington, D.C.: Office of the Surgeon General, Department of the Army. Croft, A. M. (2007). A lesson learnt: The rise and fall of lariam and halfan. Journal of the Royal Society of Medicine, 100(4), 170-174. Deye, G. A., & Magill, A. J. (2014). Primaquine for prophylaxis of malaria: Has the CYP sailed? Journal of Travel Medicine, 21(1), 67-69. Dondorp, A. M., Nosten, F., Yi, P., Das, D., Phyo, A. P., Tarning, J., (2009). Artemisinin resistance in plasmodium falciparum malaria. The New England Journal of Medicine, 361(5), 455-467. Dow, G. S., Heady, T. N., Bhattacharjee, A. K., Caridha, D., Gerena, L., Gettayacamin, M., (2006). Utility of alkylaminoquinolinyl methanols as new antimalarial drugs. Antimicrobial Agents and Chemotherapy, 50(12), 4132-4143. Dow, G. S., Milner, E., Bathurst, I., Bhonsle, J., Caridha, D., Gardner, S., (2011). Central nervous system exposure of next generation quinoline methanols is reduced relative to mefloquine after intravenous dosing in mice. Malaria Journal, 10, 150-2875-10-150. Farooq, U., & Mahajan, R. C. (2004). Drug resistance in malaria. Journal of Vector Borne Diseases, 41(3-4), 45-53. Faurant, C. (2011). From bark to weed: The history of artemisinin. Parasite (Paris, France), 18(3), 215-218. Findley, T. (1968). Sappington’s anti-fever pills and the westward migration. Transactions of the American Clinical and Climatological Association, 79, 34-44. Foley, M., & Tilley, L. (1998). Quinoline antimalarials: Mechanisms of action and resistance and prospects for new agents. Pharmacology & Therapeutics, 79(1), 55-87. Ganesan, S., Chaurasiya, N. D., Sahu, R., Walker, L. A., & Tekwani, B. L. (2012). Understanding the mechanisms for metabolism-linked hemolytic toxicity of primaquine against glucose 6- phosphate dehydrogenase deficient human erythrocytes: Evaluation of eryptotic pathway. Toxicology, 294(1), 54-60. Ganesan, S., Tekwani, B. L., Sahu, R., Tripathi, L. M., & Walker, L. A. (2009). Cytochrome P(450)- dependent toxic effects of primaquine on human erythrocytes. Toxicology and Applied Pharmacology, 241(1), 14-22. George, C. R. (2009). Blackwater fever: The rise and fall of an exotic disease. Journal of Nephrology, 22 Suppl 14, 120-128. Goncalves, L. A., Cravo, P., & Ferreira, M. U. (2014). Emerging plasmodium vivax resistance to chloroquine in south america: An overview. Memorias do Instituto Oswaldo Cruz, 109(5), 534-539. Hanboonkunupakarn, B., Ashley, E. A., Jittamala, P., Tarning, J., Pukrittayakamee, S., Hanpithakpong, W., (2014). An open-label crossover study of primaquine and dihydroartemisinin-piperaquine pharmacokinetics in healthy adult thai subjects. Antimicrobial Agents and Chemotherapy, Hue, N. T., Charlieu, J. P., Chau, T. T., Day, N., Farrar, J. J., Hien, T. T., (2009). Glucose-6- phosphate dehydrogenase (G6PD) mutations and haemoglobinuria syndrome in the vietnamese population. Malaria Journal, 8, 152-2875-8-152. Kime, P. (2012, April 11). New concerns rising over antimalaria drug. Army Times, Kola, I., & Landis, J. (2004). Can the pharmaceutical industry reduce attrition rates? Nature